Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 15, 3, 35 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Adjuvance Technologies Inc
Aelis Farma SAS
Aether Therapeutics Inc
Allaysis LLC
Amygdala Neurosciences Inc
Ananda Scientific Inc
Aphios Corp
Assertio Holdings Inc
Astraea Therapeutics LLC
Better Life Pharmaceuticals Inc
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics Holdings Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Clear Scientific LLC
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Delix Therapeutics Inc
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Entheon Biomedical Corp
EryDel SpA
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Jazz Pharmaceuticals Plc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine MindMed Inc
Mydecine Innovations Group Inc
Myosin Therapeutics Inc
Naprogenix Inc
NFL Biosciences SAS
Novartis AG
Omeros Corp
Ovid Therapeutics Inc
P2D Inc
PAION AG
Proniras Corp
Protagenic Therapeutics Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Revive Therapeutics Ltd
Saniona AB
Sen-Jam Pharmaceutical LLC
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Vivozon Inc
Zelira Therapeutics Ltd